Pyrls vs Residipok

Pyrls is a drug reference for the most practical information focused on design and simplicity. Pyrls includes the fast information that you need for top drugs: • Naming, indications, and pharmacology • Counseling points and clinical pearls related to place in therapy, safety and monitoring for each medication • Reference tables, figures, charts, and more In-App Purchase Information and Terms of Service Information Payment will be charged to your iTunes Account at confirmation of purchase. Accounts will be charged for renewal within 24-hours prior to the end of the current period. Subscriptions will automatically renew unless canceled within 24-hours before the end of the current period. Manage your subscriptions in your iPhone Account Settings after purchase. Introductory pricing or discounts, if available, will only apply for the initial introductory period of the subscription. For information regarding the acceptable use of this app, see our Terms of Service at https://pyrls.com/terms-of-service.

Residipok is a pocket reference for licensed healthcare professionals, trainees, and medical students of accredited health-professions programs. TWO MODULES (v0.4) • MIC Lookup Choose a bacterium and an antibiotic to see the EUCAST v16.0 (2026) Clinical Breakpoint thresholds — S, I, R bands by clinical context (systemic, meningitis, urinary, high-dose). Enter an MIC value to categorise it. Special states clearly labelled when no breakpoint is published or the organism is intrinsically resistant. Built especially for pan-resistance scenarios where every threshold matters. • ESC Guideline Reference Structured Class / Level of Evidence summaries of recent ESC cardiology guidelines, covering acute coronary syndromes, heart failure, atrial fibrillation, hypertension, endocarditis, cardiomyopathies, valvular disease, pulmonary hypertension and embolism, peripheral arterial disease, dyslipidaemia, prevention, pregnancy, syncope, supraventricular tachycardia, and more. Each recommendation card links back to the original guideline on escardio.org. IMPORTANT — REFERENCE ONLY • Residipok is NOT a medical device. • It does NOT diagnose, treat, cure, or prevent disease. • It is NOT a substitute for clinical judgement or for the original published guideline / breakpoint table. • Always verify against the current EUCAST table and the latest ESC document before clinical reporting. Requires confirmation of HCP / trainee status on first launch. Sign-in by email, Apple, or Google. Sources: EUCAST Clinical Breakpoint Tables v16.0 (2026); European Society of Cardiology Clinical Practice Guidelines (2018–2024).